Catalyst Brief

← Calendar

Readoutin 14d

Atea Pharmaceuticals, Inc. — Bemnifosbuvir-Ruzasvir

Phase 3 primary completion: C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV.

Date
Dec 2026
Type
Readout
Indication
HEPATITIS C VIRUS CHRONIC INFECTION

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.